Fmr LLC Purchases 5,370,392 Shares of Perspective Therapeutics, Inc. (NYSE:CATX)

FMR LLC lifted its position in Perspective Therapeutics, Inc. (NYSE:CATX - Free Report) by 3,994.9% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 5,504,822 shares of the company's stock after buying an additional 5,370,392 shares during the quarter. FMR LLC owned about 8.16% of Perspective Therapeutics worth $73,489,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also recently bought and sold shares of the stock. The Manufacturers Life Insurance Company raised its stake in Perspective Therapeutics by 8.9% during the 3rd quarter. The Manufacturers Life Insurance Company now owns 20,514 shares of the company's stock valued at $274,000 after purchasing an additional 1,672 shares during the last quarter. Sykon Capital LLC raised its stake in shares of Perspective Therapeutics by 4.7% in the 2nd quarter. Sykon Capital LLC now owns 37,932 shares of the company's stock valued at $378,000 after buying an additional 1,717 shares in the last quarter. US Bancorp DE raised its stake in shares of Perspective Therapeutics by 142.7% in the 3rd quarter. US Bancorp DE now owns 6,576 shares of the company's stock valued at $88,000 after buying an additional 3,866 shares in the last quarter. nVerses Capital LLC acquired a new position in shares of Perspective Therapeutics in the 3rd quarter valued at $57,000. Finally, Intech Investment Management LLC acquired a new position in shares of Perspective Therapeutics in the 3rd quarter valued at $137,000. 54.66% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Perspective Therapeutics

In related news, Director Heidi Henson purchased 25,975 shares of the firm's stock in a transaction on Wednesday, December 4th. The shares were acquired at an average price of $3.85 per share, for a total transaction of $100,003.75. Following the purchase, the director now directly owns 25,975 shares in the company, valued at $100,003.75. This trade represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Johan M. Spoor purchased 14,500 shares of the firm's stock in a transaction on Monday, November 25th. The stock was bought at an average price of $3.78 per share, for a total transaction of $54,810.00. Following the purchase, the chief executive officer now owns 152,072 shares in the company, valued at approximately $574,832.16. This represents a 10.54 % increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last quarter, insiders have bought 67,570 shares of company stock worth $256,789. 3.52% of the stock is owned by corporate insiders.

Perspective Therapeutics Trading Up 1.1 %

Shares of NYSE:CATX traded up $0.04 during trading on Friday, reaching $3.76. The stock had a trading volume of 1,456,198 shares, compared to its average volume of 853,123. The firm's fifty day moving average is $9.75 and its 200 day moving average is $11.92. Perspective Therapeutics, Inc. has a 52 week low of $2.28 and a 52 week high of $19.05.

Perspective Therapeutics (NYSE:CATX - Get Free Report) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.21) earnings per share for the quarter, hitting the consensus estimate of ($0.21). The business had revenue of $0.37 million for the quarter. Perspective Therapeutics had a negative net margin of 4,096.66% and a negative return on equity of 27.40%. Equities analysts expect that Perspective Therapeutics, Inc. will post -0.88 earnings per share for the current year.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on the stock. Bank of America lowered shares of Perspective Therapeutics from a "buy" rating to a "neutral" rating and lowered their target price for the stock from $24.00 to $5.00 in a report on Monday, November 25th. Oppenheimer lowered their target price on shares of Perspective Therapeutics from $22.00 to $16.00 and set an "outperform" rating on the stock in a report on Friday, November 22nd. Truist Financial assumed coverage on shares of Perspective Therapeutics in a report on Wednesday, September 25th. They issued a "buy" rating and a $21.00 target price on the stock. Royal Bank of Canada decreased their price objective on shares of Perspective Therapeutics from $25.00 to $16.00 and set an "outperform" rating on the stock in a report on Monday, November 25th. Finally, Wedbush reissued an "outperform" rating and set a $11.00 price objective (down previously from $20.00) on shares of Perspective Therapeutics in a report on Thursday, November 21st. One equities research analyst has rated the stock with a hold rating and eight have given a buy rating to the company's stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $15.14.

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.